U.S. Doctors Seeking Details on Federal Distribution of Gilead COVID-19 Drug
The Infectious Disease Society of America is asking for more information on the federal government’s plan for deciding how and where to produce the one drug so far proven to help sufferers infected with the novel coronavirus.
The U.S. Food and Drug Administration (FDA) Friday gave emergency use authorization to Gilead Sciences’ remdesivir for sufferers with extreme COVID-19 – the illness caused by the coronavirus – clearing the way for broader use in more hospitals around the U.S.
The federal government started distributing the drug this week. However, doctors across the nation, significantly in COVID-19 hotspots like New York and Boston, became concerned after being denied their request to obtain the brand new therapy, IDSA president Dr. Thomas File said Thursday.
The IDSA Wednesday called on the Trump Administration to clarify how it will ensure equitable distribution of remdesivir to states and hospitals based on COVID-19 case and hospitalization rates.
The doctor group stressed the importance of truthful allocation to health in communities disproportionately affected by the coronavirus, along with African American and Hispanic populations.
The IDSA mentioned it didn’t know how many hospitals had so far been approved to receive remdesivir or how many had been turned down.
Gilead last week donated 1.5 million vials of the drug to U.S. hospitals, sufficient to treat at least 140,000 sufferers.
The Federal Emergency Management Agency (FEMA) and the Division of Health and Human Services (HHS) are coordinating the donation and distribution of remdesivir.